Funds for the new danish findings on Covid-19

by Catalina Pérez

Front entrence of the University of Copenhagen. Photo by Catalina Pérez.

Copenhagen. At the University of Copenhagen, a vaccine with new technology was created. Last week, the three main researchers were in quarantine after arriving from Holland, the country where the first humans have been vaccinated with their vaccine.

It is the clinical part of the first phase of the trial of this drug. If it succeeds it will allow lowering the cost of distributing and producing the dose against Covid-19.

The process had taken one year, “very short period of time” explain Dr. Morten Agertoug Nielsen, one of the academics who participated in the development of the corona vaccine. To patent the new technology that allows maintaining the doses at higher temperatures, the ADAPTVAC enterprise was created.

They received the Horizon 2020 fund of the European Union in March last year. But to advance the research at the clinical phase, they need more financial help. They reached out to Bavarian Nordic, a Danish Laboratory that is funding the trial on humans.

More funds to be expected 

For the highest cost and the risk of failure “it is almost impossible to create a vaccine just with public funds”, says Dr. Agertoug. He explains that for university researchers it is difficult to attract the attention of private investors. But he emphasizes that with the pandemic more states and privates are interested in developing new technologies for vaccines, which quickens the investigation against Covid-19.

“In a few years, we will see the results of an increase of investors during the pandemic, interested in new technologies to create and develop vaccines”, concluded the academic.